National Health Act 1953 - Amendment determination under paragraph 98C(1)(b) - conditions (No. PB 82 of 2007)

Overview

The National Health Act 1953, enacted by the Australian Parliament, serves as the legislative foundation for the Pharmaceutical Benefits Scheme (PBS), which ensures all Australians have reliable, timely, and affordable access to a wide range of medicines. The Act provides the framework for the Commonwealth to offer pharmaceutical benefits, with the Minister declaring listed drugs and determining their forms, administration, and brands. A key aspect of the Act is its provision for the Minister to set conditions for payments regarding the supply of pharmaceutical benefits by approved pharmacists and medical practitioners. The legislative instrument F2007L03946, made on 2 October 2007 and commencing on 1 November 2007, amends the conditions under which these payments are made, aligning with the policy objective of refining the operational framework of the PBS for better efficiency and effectiveness. This instrument follows recommendations from the Pharmaceutical Benefits Advisory Committee, which assesses the clinical effectiveness, safety, and cost-effectiveness of medicines before recommending their inclusion on the PBS.

Scope and Application

The National Health Act 1953, as amended, establishes the Pharmaceutical Benefits Scheme (PBS) under which the Commonwealth provides accessible, reliable, and affordable access to a wide range of medicines for all Australians. Specifically, Part VII of the Act governs the supply of pharmaceutical benefits, with drugs and medicinal preparations declared by the Minister to be subject to the PBS listed under section 85. The Act applies to approved pharmacists and approved medical practitioners who supply these pharmaceutical benefits. The Minister can determine the form, administration, and brands of pharmaceutical items through subordinate instruments. The Act's jurisdiction is national, with its provisions extending across the Commonwealth of Australia. The conditions under which payments will be made for the supply of these pharmaceutical benefits are determined by legislative instruments under section 98C(1)(b), with the current determinations being those set out in PB 82 of 2007, which amends the previous determination PB 52 of 2007 and came into effect on 1 November 2007. The Pharmaceutical Benefits Advisory Committee advises the Minister on recommendations for which drugs and medicinal preparations should be available under the PBS, ensuring that decisions are based on clinical effectiveness, safety, and cost-effectiveness.

Key Provisions

The operative sections of this legislative instrument primarily concern amendments to the determination under section 98C(1)(b) of the National Health Act 1953. This amendment, as per Schedule 1 of the instrument, modifies the previous determination made by legislative instrument number PB 52 of 2007, which came into effect on 1 August 2007. Specifically, the amendments involve changes to the definitions and conditions governing the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners, effective from 1 November 2007. The instrument aims to refine the process by which the Commonwealth provides pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS), ensuring that the supply of medicines remains reliable, timely, and affordable for all Australians. The Act imposes several obligations on the parties involved in the supply of pharmaceutical benefits. Firstly, the Pharmaceutical Benefits Advisory Committee (PBAC) must recommend whether a drug or medicinal preparation should be listed on the PBS, taking into account factors such as clinical effectiveness, safety, and cost-effectiveness. The Minister for Health and Ageing is then required to consider these recommendations before making a determination under section 98C(1)(b) of the Act. Additionally, approved pharmacists and approved medical practitioners must adhere to the conditions set forth in the determination to be eligible for payments from the Commonwealth for the supply of pharmaceutical benefits. These conditions include the proper administration of the pharmaceutical items, the appropriate manner of dispensing, and the compliance with the declared forms and brands of the listed drugs. Any breaches of the conditions set by the Act can lead to civil or criminal consequences. Although the instrument does not explicitly detail penalties, it is implied that non-compliance with the PBS regulations can result in the withholding of payments from the Commonwealth. Furthermore, repeated or severe breaches may attract additional penalties under other provisions of the National Health Act 1953 or other relevant legislation. The exact penalties are not specified in this instrument but may include fines or other legal actions that the Commonwealth can take against those who do not adhere to the prescribed conditions for the supply of pharmaceutical benefits. The legislative instrument also clarifies the definition of terms used in the Act, such as the omission of the definition of "Tribunal Determination" from Paragraph 3 (Definitions). This omission ensures that the language used in the Act is clear and precise, reducing any potential ambiguities that could arise from the interpretation of these terms. By doing so, the instrument helps maintain the integrity of the PBS and ensures that all stakeholders, including the Commonwealth, approved pharmacists, approved medical practitioners, and the public, are well-informed about their respective roles and responsibilities.